These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22866001)

  • 1. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW
    Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R; Benhamou CL; Halse J; Miller PD; Reid IR; Rodríguez Portales JA; DaSilva C; Kroon R; Verbruggen N; Leung AT; Gurner D
    Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
    Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
    Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
    Nakamura T; Shiraki M; Fukunaga M; Tomomitsu T; Santora AC; Tsai R; Fujimoto G; Nakagomi M; Tsubouchi H; Rosenberg E; Uchida S
    Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
    Masarachia PJ; Pennypacker BL; Pickarski M; Scott KR; Wesolowski GA; Smith SY; Samadfam R; Goetzmann JE; Scott BB; Kimmel DB; Duong LT
    J Bone Miner Res; 2012 Mar; 27(3):509-23. PubMed ID: 22113859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
    Cusick T; Chen CM; Pennypacker BL; Pickarski M; Kimmel DB; Scott BB; Duong LT
    J Bone Miner Res; 2012 Mar; 27(3):524-37. PubMed ID: 22113921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
    Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
    J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
    Duong le T; Leung AT; Langdahl B
    Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
    Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
    Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.
    Pennypacker BL; Chen CM; Zheng H; Shih MS; Belfast M; Samadfam R; Duong LT
    J Bone Miner Res; 2014 Aug; 29(8):1847-58. PubMed ID: 24591096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
    Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
    Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS; Harsløf T; Langdahl B
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
    Recker R; Dempster D; Langdahl B; Giezek H; Clark S; Ellis G; de Villiers T; Valter I; Zerbini CA; Cohn D; Santora A; Duong LT
    J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K; Chattopadhyay N
    Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cathepsin K antagonists: preclinical and clinical data].
    Gamsjäger M; Resch H
    Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.